Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics

Prothena Corporation plc - Ordinary Shares (PRTA): $51.43

1.07 (-2.04%)

POWR Rating

Component Grades








Add PRTA to Watchlist
Sign Up

Industry: Biotech




#150 of 362

in industry

PRTA Price/Volume Stats

Current price $51.43 52-week high $79.65
Prev. close $52.50 52-week low $28.99
Day low $51.21 Volume 206,810
Day high $52.42 Avg. volume 445,964
50-day MA $59.69 Dividend yield N/A
200-day MA $59.23 Market Cap 2.75B

PRTA Stock Price Chart Interactive Chart >


  • PRTA scores best on the Growth dimension, with a Growth rank ahead of 71.46% of US stocks.
  • PRTA's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • PRTA's current lowest rank is in the Stability metric (where it is better than 14.41% of US stocks).

PRTA Stock Summary

  • PRTA's price/sales ratio is 48.79; that's higher than the P/S ratio of 96.62% of US stocks.
  • With a year-over-year growth in debt of -64%, PROTHENA CORP PUBLIC LTD CO's debt growth rate surpasses merely 3.53% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, PROTHENA CORP PUBLIC LTD CO is reporting a growth rate of 3,368.28%; that's higher than 99.62% of US stocks.
  • Stocks that are quantitatively similar to PRTA, based on their financial statements, market capitalization, and price volatility, are IONS, MRUS, RNA, CCCC, and ENTA.
  • PRTA's SEC filings can be seen here. And to visit PROTHENA CORP PUBLIC LTD CO's official web site, go to

PRTA Valuation Summary

  • In comparison to the median Healthcare stock, PRTA's price/earnings ratio is 173.39% lower, now standing at -20.
  • Over the past 131 months, PRTA's EV/EBIT ratio has gone down 9.7.

Below are key valuation metrics over time for PRTA.

Stock Date P/S P/B P/E EV/EBIT
PRTA 2023-09-18 48.8 4.8 -20.0 -14.0
PRTA 2023-09-15 48.7 4.8 -19.9 -14.0
PRTA 2023-09-14 50.3 5.0 -20.6 -14.6
PRTA 2023-09-13 50.2 5.0 -20.5 -14.5
PRTA 2023-09-12 51.5 5.1 -21.0 -15.0
PRTA 2023-09-11 50.6 5.0 -20.7 -14.7

PRTA Growth Metrics

    Its 4 year revenue growth rate is now at -26.69%.
  • The 3 year revenue growth rate now stands at 21953.61%.
  • Its 5 year price growth rate is now at -76.52%.
PRTA's revenue has moved down $55,594,000 over the prior 15 months.

The table below shows PRTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 5.154 -126.303 -156.477
2022-06-30 142.811 16.974 -1.466
2022-03-31 201.57 88.856 67.42
2021-12-31 200.577 92.605 66.975
2021-09-30 199.765 95.969 69.438
2021-06-30 60.748 -35.545 -70.386

PRTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRTA has a Quality Grade of B, ranking ahead of 82.12% of graded US stocks.
  • PRTA's asset turnover comes in at 0.448 -- ranking 99th of 682 Pharmaceutical Products stocks.
  • RYTM, EVOK, and EVFM are the stocks whose asset turnover ratios are most correlated with PRTA.

The table below shows PRTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.448 1 4.191
2021-06-30 0.161 1 -2.858
2021-03-31 0.002 1 -3.400
2020-12-31 0.002 1 -2.721
2020-09-30 0.002 1 -2.229
2020-06-30 0.002 1 -1.819

PRTA Price Target

For more insight on analysts targets of PRTA, see our PRTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.40 Average Broker Recommendation 1.31 (Strong Buy)

Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Latest News Stream

Event/Time News Detail
Loading, please wait...

PRTA Latest Social Stream

Loading social stream, please wait...

View Full PRTA Social Stream

Latest PRTA News From Around the Web

Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Pinning Down Prothena Corporation plc's (NASDAQ:PRTA) P/S Is Difficult Right Now

You may think that with a price-to-sales (or "P/S") ratio of 48.7x Prothena Corporation plc ( NASDAQ:PRTA ) is a stock...

Yahoo | September 16, 2023

Insider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLC

On September 13, 2023, Hideki Garren, the Chief Medical Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 2,000 shares of the company.

Yahoo | September 14, 2023

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Yahoo | September 7, 2023

Prothena to Participate in Upcoming Healthcare Conferences

DUBLIN, August 31, 2023--Prothena announced that members of its senior management team will participate in upcoming investor conferences.

Yahoo | August 31, 2023

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Yahoo | August 4, 2023

Read More 'PRTA' Stories Here

PRTA Price Returns

1-mo -10.01%
3-mo -26.30%
6-mo 9.26%
1-year 64.26%
3-year 402.74%
5-year 285.53%
YTD -14.64%
2022 21.96%
2021 311.32%
2020 -24.13%
2019 53.69%
2018 -72.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!